Patent SG-11201804857W-A (SG)
Title: Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
Inventor: HSU HAILING
IPC: C07K16/24
Filed: 2016-12-14
Abstract: v) (v3) 3S5! (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106383 A4 22 June 2017 (22.06.2017) WIPO I PCT (51) International Patent Classification: C07K 16/24 (2006.01) (21) International Application Number: PCT/US2016/066722 (22) International Filing Date: 14 December 2016 (14.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/268,432 16 December 2015 (16.12.2015) US 62/333,063 6 May 2016 (06.05.2016) US PCT/US2016/052006 15 September 2016 (15.09.2016) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: HSU, Hailing; 7264 Littler Court, Moorpark, California 93021 (US). KANNAN, Gunasekaran; 151 Crestview Circle, Daly City, California 94015 (US). WALKER, Kenneth W.; 175 Mesa Avenue, Newbury Park, California 91320 (US). HORTTER, Michelle; 455 Mariposa Drive, Camarillo, California 93012 (US). BE- LOUSKI, Edward J.; 761 Camino Las Conchas, Thou- sand Oaks, California 91360 (US). (74) Agents: GAUL, Timothy J. et al.; Amgen Inc., One Am- gen Center Drive, Thousand Oaks, California 91320-1799 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) [Continued on next page] — (54) Title: ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF 1111111111111101110101011111010111110 010110111111011111111011111111111011111111 (v4) K392D :356K K4090 399K K3700 357K W O 20 17 / 106383 A4 HC1 SISaK HC1 039K & • .6.3K HC1 48K & S .61 . HC1 SifLi HC2 S183E HC2 039E & S183E HC2 G44E & S183E HC2 S183E LC1 S176E LC1 0.38E & S176E LC1 GlOOE & S176E LC1 S176E LC2 S176K LC2 038K & S: 76K LC2 i100K & S .76K LC2 S176k Fig_ 1 (57) : The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding pro- teins (e.g., antibodies) to TL1A and TNF-a. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-a. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-alpha antigen binding proteins, and pharmaceutical formulations thereof. WO 2017/106383 A4 MIDEDIMOMOIDEIRMEMOMM1110110MMOMEION with amended claims (Art. 190)) Date of publication of the amended claims: 8 September 2017 with sequence listing part of description (Rule 5.2(a))